Paper32255486
Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
Nayagam S and 23 others. Clin Infect Dis, 2021. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning. Papers, record 32255486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32255486
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B | Major topic |
| Hepatitis B, Chronic | Major topic |
| Antiviral Agents | |
| China | |
| Hepatitis B Vaccines | |
| Hepatitis B virus | |
| Humans |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 001 | World Health Organization | International | PubMed | |
| MC_PC_19012 | Medical Research Council | United Kingdom | PubMed | |
| MR/L002086/1 | Medical Research Council | United Kingdom | PubMed | |
| MR/R015600/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 32255492 | Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive. | https://conductscience.org/library/papers/32255492 |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26146815 | World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. | Hepatology | 2015 | https://conductscience.org/library/papers/26146815 | PubMed |
| 2 | 27751400 | The effects of China's universal two-child policy. | Lancet | 2016 | https://conductscience.org/library/papers/27751400 | PubMed |
| 3 | 24004482 | The economic costs of malaria in children in three sub-Saharan countries: Ghana, Tanzania and Kenya. | Malar J | 2013 | https://conductscience.org/library/papers/24004482 | PubMed |
| 4 | 29599078 | Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. | Lancet Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/29599078 | PubMed |
| 5 | 21641026 | Towards an improved investment approach for an effective response to HIV/AIDS. | Lancet | 2011 | https://conductscience.org/library/papers/21641026 | PubMed |
| 6 | 20553944 | Dynamical behavior of a hepatitis B virus transmission model with vaccination. | J Theor Biol | 2010 | https://conductscience.org/library/papers/20553944 | PubMed |
| 7 | 26808342 | Cancer statistics in China, 2015. | CA Cancer J Clin | 2016 | https://conductscience.org/library/papers/26808342 | PubMed |
| 8 | 26804359 | Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature. | Health Econ | 2016 | https://conductscience.org/library/papers/26804359 | PubMed |
| 9 | 20586991 | Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. | Value Health | 2009 | https://conductscience.org/library/papers/20586991 | PubMed |
| 10 | 17495790 | Progress in hepatitis B prevention through universal infant vaccination--China, 1997-2006. | MMWR Morb Mortal Wkly Rep | 2007 | https://conductscience.org/library/papers/17495790 | PubMed |
| 11 | 16249217 | A mathematical model to estimate global hepatitis B disease burden and vaccination impact. | Int J Epidemiol | 2005 | https://conductscience.org/library/papers/16249217 | PubMed |
| 12 | 8241859 | Cost-benefit analysis. | BMJ | 1993 | https://conductscience.org/library/papers/8241859 | PubMed |
| 13 | 25329072 | Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China. | PLoS One | 2014 | https://conductscience.org/library/papers/25329072 | PubMed |
| 14 | 24653626 | Annual report on status of cancer in China, 2010. | Chin J Cancer Res | 2014 | https://conductscience.org/library/papers/24653626 | PubMed |
| 15 | 28418296 | Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. | Emerg Infect Dis | 2017 | https://conductscience.org/library/papers/28418296 | PubMed |
| 16 | 26231459 | Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. | Lancet | 2015 | https://conductscience.org/library/papers/26231459 | PubMed |
| 17 | 21998648 | Economic returns to investment in AIDS treatment in low and middle income countries. | PLoS One | 2011 | https://conductscience.org/library/papers/21998648 | PubMed |
| 18 | 24670067 | The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. | BMC Cancer | 2014 | https://conductscience.org/library/papers/24670067 | PubMed |
| 19 | 15602167 | Cost of chronic hepatitis B infection in China. | J Clin Gastroenterol | 2004 | https://conductscience.org/library/papers/15602167 | PubMed |
| 20 | 27638356 | Requirements for global elimination of hepatitis B: a modelling study. | Lancet Infect Dis | 2016 | https://conductscience.org/library/papers/27638356 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42483732 | Chronic Hepatitis B in the Asia-Pacific Region: Results of the 2023 Global Burden of Disease Study. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/42483732 | PubMed |
| 42277148 | Spatio-temporal clustering characteristics of hepatitis B in China: an 18-year study. | Sci Rep | 2026 | https://conductscience.org/library/papers/42277148 | PubMed |
| 42050466 | Medication adherence and associated factors in patients with chronic hepatitis B in Zhejiang Province, Eastern China. | BMC Public Health | 2026 | https://conductscience.org/library/papers/42050466 | PubMed |
| 41263854 | Curative care expenditure across different comorbidity states of chronic hepatitis B: a prevalence study in Sichuan Province, China. | BMJ Open | 2025 | https://conductscience.org/library/papers/41263854 | PubMed |
| 41127124 | Feasibility of eliminating adult hepatitis B in Guangdong by 2030: A modeling study. | Infect Dis Model | 2026 | https://conductscience.org/library/papers/41127124 | PubMed |
| 40937078 | Epidemiology, Achievements, and Challenges in the Elimination of Hepatitis B in China. | J Clin Transl Hepatol | 2025 | https://conductscience.org/library/papers/40937078 | PubMed |
| 40265061 | Changes in the prevalence of hepatitis B virus and its related factors in Inner Mongolia between 2006 and 2020. | Front Public Health | 2025 | https://conductscience.org/library/papers/40265061 | PubMed |
| 40104634 | Modeling hepatitis B-related deaths in China to achieve the WHO's impact target. | Infect Dis Model | 2025 | https://conductscience.org/library/papers/40104634 | PubMed |
| 40044428 | [Recent advances in epidemiology, prevention and treatment of hepatitis B in China]. | Zhonghua Gan Zang Bing Za Zhi | 2025 | https://conductscience.org/library/papers/40044428 | PubMed |
| 39680440 | Effect of Health Literacy on Antiviral Treatment of Hepatitis B: Instrumental Variable Analysis. | JMIR Public Health Surveill | 2024 | https://conductscience.org/library/papers/39680440 | PubMed |
| 39315090 | New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. | Lancet Reg Health West Pac | 2024 | https://conductscience.org/library/papers/39315090 | PubMed |
| 38660313 | Comparison of the effectiveness four years after Homo/Hetero prime-boost with 10 μg HP and 20 μg CHO recombinant hepatitis B vaccine at 1 and 6 months in maternal HBsAg-negative children. | Front Immunol | 2024 | https://conductscience.org/library/papers/38660313 | PubMed |
| 38176692 | Comprehensive approach to controlling chronic hepatitis B in China. | Clin Mol Hepatol | 2024 | https://conductscience.org/library/papers/38176692 | PubMed |
| 37675271 | Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies. | JHEP Rep | 2023 | https://conductscience.org/library/papers/37675271 | PubMed |
| 37349664 | Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study. | J Epidemiol Glob Health | 2023 | https://conductscience.org/library/papers/37349664 | PubMed |
| 36747172 | Changing incidence of hepatitis B and persistent infection risk in adults: a population-based follow-up study from 2011 in China. | BMC Public Health | 2023 | https://conductscience.org/library/papers/36747172 | PubMed |
| 36423153 | Exploring the Public Health and Social Implications of Future Curative Hepatitis B Interventions. | Viruses | 2022 | https://conductscience.org/library/papers/36423153 | PubMed |
| 35836769 | Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. | J Clin Transl Hepatol | 2022 | https://conductscience.org/library/papers/35836769 | PubMed |
| 35796158 | Costs and health impact of delayed implementation of a national hepatitis B treatment program in China. | J Glob Health | 2022 | https://conductscience.org/library/papers/35796158 | PubMed |
| 35198638 | Question Answering System Based on Knowledge Graph in Traditional Chinese Medicine Diagnosis and Treatment of Viral Hepatitis B. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/35198638 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32255486
GET https://conductscience.org/api/papers/v1/32255486/authors?page=2